Bilateral primary fallopian tube carcinoma is a rare diagnosis in our gynaecological practice. Very often, the diagnosis is mistaken for an ovarian carcinoma or a tubo-ovarian mass. A correct, preoperative diagnosis is made only in 4% of the cases. This is due to the nonspecific symptoms. The Latzko's triad of a watery vaginal discharge, a colicky lower abdominal pain and a pelvic mass is typical of a fallopian tube carcinoma, but this triad is noted only in less than 15% of the patients. Here, we are reporting such a case where the patient presented with all the classical features of a primary fallopian tube carcinoma. This case is also being reported for it's extreme rarity.
Sertoli-Leydig Cell Tumors (SLCT) comprises an uncommon and heterogeneous group of ovarian neoplasms within sex-cord stromal category. Retiform type accounts to about 10-15% of all SLCTs and they are less androgenic than other variants. We present to you a 20 year old lady who came to us with features of virilisation and abdominal mass. Intra-operatively, mass arose from left ovary. Left salpingo-oophorectomy was done. Histopathological diagnosis was SLCT with retiform pattern and with a foci of heterologous elements. Interestingly, patient had undergone hemithyroidectomy at the age of 9 for thyroid adenoma. As a part of pre-operative work up, computed tomography revealed an incidental finding of adrenal adenoma but overnight dexamethasone suppression test was negative. There have been reports of association of thyroid conditions with SLCT but here we are reporting association of two endocrine glands (thyroid and adrenal) in the same patient. [Int J Reprod Contracept Obstet Gynecol 2012; 1(1.000): 55-57
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.